A novel model for predicting immunotherapy response and prognosis in NSCLC patients
Abstract Background How to screen beneficiary populations has always been a clinical challenge in the treatment of non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs). Routine blood tests, due to their advantages of being minimally invasive, convenient, and capable of reflect...
Saved in:
| Main Authors: | Ting Zang, Xiaorong Luo, Yangyu Mo, Jietao Lin, Weiguo Lu, Zhiling Li, Yingchun Zhou, Shulin Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03800-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC
by: Jia Yu, et al.
Published: (2025-06-01) -
CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
by: Antoine Desilets, MD, MSc, et al.
Published: (2024-12-01) -
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window
by: Kaibo Ding, et al.
Published: (2025-03-01) -
The role of novel risk-scoring systems in predicting the efficacy of immunotherapy
by: Yu.V. Moskalenko
Published: (2025-02-01) -
Immunotherapy for Extensive-stage Small Cell Lung Cancer:
Research Progress and Future Perspectives
by: Yuling ZHONG, et al.
Published: (2024-11-01)